US › Healthcare

Satellos Bioscience Inc. Common Stock (MSLE)

US · Healthcare · Biotechnology

$9.68+4.09%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-11.4M

EPS

$-0.56

EPS estimate

$-0.38

EPS came in at -0.56 against a street estimate of -0.38 — a miss of 47.4%.

Key statistics

Market cap

$206.9M

Forward P/E

0.0

P/B

3.43

Book value

$2.88

EPS (TTM)

$-1.95

52-week high

$13.39

52-week low

$5.30

50-day MA

$9.42

200-day MA

$8.20

Beta

1.14

Analyst view

with an average price target of $26.25.

Shareholding

Insiders

6.37%

Institutions

49.70%

Largest institutional holders

Fund	Stake
Franklin Templeton Inc	4.42%
Siren, L.L.C.	4.20%
Vivo Capital, LLC	3.84%
Point72 Asset Management, L.P.	3.26%
Woodline Partners LP	2.36%
Sphera Funds Management Ltd.	2.31%
Suvretta Capital Management, LLC	2.24%
Avidity Partners Management LP	1.83%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Satellos Bioscience Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.